We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adma Biologics (ADMA - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Adma Biologics is one of 1089 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Adma Biologics is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ADMA's full-year earnings has moved 57.9% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, ADMA has gained about 0.5% so far this year. At the same time, Medical stocks have lost an average of 6.8%. This means that Adma Biologics is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Aurinia Pharmaceuticals (AUPH - Free Report) . The stock has returned 103.9% year-to-date.
The consensus estimate for Aurinia Pharmaceuticals' current year EPS has increased 11.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adma Biologics belongs to the Medical - Biomedical and Genetics industry, which includes 528 individual stocks and currently sits at #59 in the Zacks Industry Rank. This group has lost an average of 19.8% so far this year, so ADMA is performing better in this area.
On the other hand, Aurinia Pharmaceuticals belongs to the Medical - Drugs industry. This 194-stock industry is currently ranked #69. The industry has moved -8.9% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Adma Biologics and Aurinia Pharmaceuticals as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adma Biologics (ADMA - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Adma Biologics is one of 1089 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Adma Biologics is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ADMA's full-year earnings has moved 57.9% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, ADMA has gained about 0.5% so far this year. At the same time, Medical stocks have lost an average of 6.8%. This means that Adma Biologics is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Aurinia Pharmaceuticals (AUPH - Free Report) . The stock has returned 103.9% year-to-date.
The consensus estimate for Aurinia Pharmaceuticals' current year EPS has increased 11.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adma Biologics belongs to the Medical - Biomedical and Genetics industry, which includes 528 individual stocks and currently sits at #59 in the Zacks Industry Rank. This group has lost an average of 19.8% so far this year, so ADMA is performing better in this area.
On the other hand, Aurinia Pharmaceuticals belongs to the Medical - Drugs industry. This 194-stock industry is currently ranked #69. The industry has moved -8.9% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Adma Biologics and Aurinia Pharmaceuticals as they could maintain their solid performance.